Photopharmica
Investors Count
4Funding, Valuation & Revenue
1 Fundings
Photopharmica's latest funding round was a Other Investors for on .
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
Other Investors |
Date | |
|---|---|
Round | Other Investors |
Amount | |
Investors | |
Valuation | |
Revenue | |
Sources |
This profile has not been claimed.
You're more than your latest funding, tell our customers your company's story.
Photopharmica Investors
4 Investors
Photopharmica has 4 investors. IP Group invested in Photopharmica's Other Investors funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
1 Other Investors | Venture Capital | United Kingdom | ||||
Asset/Investment Management | United Kingdom | |||||
Academic/University | ||||||
Venture Capital |
First funding | ||||
|---|---|---|---|---|
Last Funding | ||||
Investor | ||||
Rounds | 1 Other Investors | |||
Board Seats | ||||
Type | Venture Capital | Asset/Investment Management | Academic/University | Venture Capital |
Location | United Kingdom | United Kingdom |
Compare Photopharmica to Competitors
LaGray is engaged in the research and development of drugs for the treatment of endemic diseases in Sub-Saharan Africa.
PharmaSurgics develops and commercialises a treatment for the prevention of harmful scarring (adhesions)
Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.
Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn
Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).
Topica provides marketing and sales solutions for businesses with online channels. Topica's solution enables businesses and organizations world-wide to find new prospective customers and sell more online. Using Topica, online marketers better leverage their current marketing initiatives, such as paid search, affiliate programs and display advertising, as they turn more traffic into first-time buyers and loyal long term customers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.